Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Next Previous
X
Search
Trial Profile

A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Results of pooled analysis from NCT04160052, NCT04550442,NCT04655755 ,explaining resistance of GMP pattern and MDS to venetoclax therapy presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 15 Jun 2023 Results of pooled analysis from NCT04160052, NCT04550442,NCT04655755 assessing patient and disease characteristics associated with overall response rate (ORR), event-free survival (EFS),and overall survival (OS) in prospective studies of HMA + VEN in HR-MDS presented at the 28th Congress of the European Haematology Association
    • 04 May 2023 Planned End Date changed from 11 May 2023 to 11 May 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top